1. Neoadjuvant Chemotherapy Improves Outcomes in Resectable Distal Pancreatic Adenocarcinoma. (2022) Authors: Marcus, R.; Christopher, W.; Nassoiy, S.; Keller, J.; Chang, S.-C.; Goldfarb, M.; Jutric, Z.; Wolf, R. Journal: HPB Issue: Volume 24(2022)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma: an updated national cancer database analysis. (2021) Authors: Christopher, W.; Nassoiy, S.; Keller, J.; Marcus, R.; Chang, S.C.; Fischer, T.; Goldfarb, M.; Bilchik, A. Journal: HPB Issue: Volume 23(2021)Supplement 2 Page Start: S615 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Neoadjuvant chemotherapy is associated wtih lower rates of margin-positive resection of intrahepatic cholangiocarcinoma. (2021) Authors: Marcus, R.; Christopher, W.; Nassoiy, S.; Keller, J.; Chang, S.C.; Goldfarb, M.; Wolf, R.; Jutric, Z. Journal: HPB Issue: Volume 23(2021)Supplement 2 Page Start: S520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Neoadjuvant Chemotherapy Is Associated Wtih Lower Rates of Margin-Positive Resection of Intrahepatic Cholangiocarcinoma. (2022) Authors: Marcus, R.; Christopher, W.; Keller, J.; Nassoiy, S.; Goldfarb, M.; Wolf, R.; Jutric, Z. Journal: HPB Issue: Volume 24(2022)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗